Ultragenyx Pharmaceutical Announces UX701 AAV9 Gene Therapy To Treat Wilson Disease Failed To Meet Criteria, Being Terminated
Benzinga Newsdesk 1 day ago
News
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced it is
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced it is terminating UX701 for Wilson disease based on not achieving study goals.